#Switzerland #Diabetes Care #Basel #Continuous Glucose Monitoring #FiberSense

FiberSense Achieves CE Mark for Its Continuous Glucose Monitoring System

In an impressive milestone for medical technology, FiberSense AG has announced that its Continuous Glucose Monitoring (CGM) system has received the coveted CE mark, signalling compliance with European Union medical device regulations. This significant achievement marks a critical step towards commercial availability and aims to enhance daily diabetes management for individuals living with this condition.

A Technological Breakthrough

The FiberSense CGM device employs cutting-edge optical detection technology to continuously measure glucose levels within the interstitial fluid of subcutaneous tissue. This innovative method allows individuals with diabetes to monitor their glucose levels in real time, facilitating better management of their condition and reducing the risks associated with fluctuating glucose levels.

The CGM is designed with practicality in mind, featuring a sensor and adhesive patch that can remain effective for up to 28 days, minimizing the need for frequent replacements. The system also includes a reusable detector and charger, making it a sustainable option for long-term glucose monitoring.

Key Statements from Leadership

Michael Tillmann, the CEO of FiberSense AG, expressed his enthusiasm for this regulatory success, stating, "This certification represents a significant milestone for FiberSense. After years of intensive development, we are now focusing on ramping up production and marketing efforts." Tillmann emphasized that the CE mark not only facilitates their entry into commercial markets but also represents the first step in their broader biomarker detection strategies.

With initial orders confirmed and the first deliveries anticipated by late 2026, the company is busy preparing its production, logistics, customer service, and market access activities to ensure a smooth launch in select markets.

Future Aspirations

While the primary application of the FiberSense CGM will focus on glucose monitoring for adults with diabetes, the company has ambitious plans for expanding its multi-analysis continuous (CxM) platform. Future sensors for ketones, lactate, and cortisol are already being evaluated, promising to revolutionize biomarker detection in various health conditions.

Tillmann noted, "The FiberSense CGM system symbolizes the first regulated application of our long-term strategy. We aim to explore additional opportunities in the continuous detection of biomarkers beyond glucose while developing a platform capable of supporting various analyses and applications, given the necessary scientific, clinical, and regulatory evidence is established."

Conclusion

The approval of the FiberSense CGM marks a pivotal moment not just for FiberSense AG but also for individuals managing diabetes. This advanced device promises to provide a reliable solution for continuous monitoring, empowering users with the information they need for effective diabetes management. As the company gears up for its commercial rollout, it holds the potential to significantly enhance the quality of life for countless individuals affected by diabetes worldwide. For further inquiries, FiberSense can be reached at +49 (0)6026 942 121 or via their website at fibersense-cxm.com.